A5018999157- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Glioma Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Prostate Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Gastric Cancer Management and Outcomes
- Multiple Myeloma Research and Treatments
- Liver Disease Diagnosis and Treatment
- Gallbladder and Bile Duct Disorders
- Colorectal Cancer Treatments and Studies
- Intraperitoneal and Appendiceal Malignancies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hormonal and reproductive studies
- Sarcoma Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- PI3K/AKT/mTOR signaling in cancer
Ospedale Generale Regionale Francesco Miulli
2020-2024
Hospital of Prato
2016-2020
Nuovo Ospedale di Prato
2016-2017
University of Siena
2014-2015
Ospedale Santa Maria alle Scotte
2014-2015
Christie's
2014
Creative Commons
2014
Policlinico Umberto I
2014
Prostate Cancer UK
2014
Food and Drug Administration
2014
In the treatment of advanced non-small cell lung cancer (NSCLC), immune checkpoint inhibitors have shown remarkable results. However, not all patients with NSCLC respond to this drug or receive durable benefits. Thus, patient stratification and selection, as well identification predictive biomarkers, represent pivotal aspects address. framework, metabolomics can be used support discrimination between responders non-responders. Here, was analyze sera samples from 50 NSCL treated inhibitors....
Immune-related liver injury (irLI) is commonly observed in patients with cancer treated immune checkpoint inhibitors (ICIs). We aimed to compare the incidence, clinical characteristics, and outcomes of irLI between receiving ICIs for hepatocellular carcinoma (HCC) vs. other solid tumours.
ObjectiveRecurrent gynecological tumors (e.g., endometrial, and ovarian cancers) are incurable diseases; therefore, new treatment options urgently needed. The PTEN-AKT-PI3K pathway is frequently altered in these tumors, representing a potential target. Alpelisib an α-specific PI3K inhibitor approved PIK3CA-mutated advanced breast cancer. We report outcomes from large series of patients with cancers prospectively treated alpelisib within controlled program.MethodsFrom April 2021 to December...
Background/Objectives: Hypofractionated radiation therapy (Hypo-RT) schedules may offer radiobiological, patient convenience, and healthcare resource advantages over standard fractionated (S-RT) for glioblastoma (GBM). Additionally, simulated integrated boost (SIB) Hypo-RT is proven to be an effective safe treatment. We report on our experience regarding progression-free survival (PFS), overall (OS), RT-related toxicities in GBM patients treated with S-RT. Methods: Patients IDH-wildtype...
Frailty increases the risk of adverse health outcomes and/or dying when exposed to a stressor, and routine frailty assessment is recommended guide treatment decision. The Balducci criteria (BFC) Fried (FFC) are commonly used, but these time consuming. Vulnerable Elders Survey-13 (VES-13) score ≥7, simple resource conserving function-based scoring system, may be used instead. This prospective study evaluates performance VES-13 in parallel with BFC FFC, identify elderly patients early-stage...
Background Until now, no robust data supported the efficacy, safety and recommendation for influenza vaccination in patients with cancer receiving immune checkpoint inhibitors (ICIs). Methods The prospective multicenter observational INfluenza Vaccine Indication During therapy Immune (INVIDIa-2) study investigated clinical effectiveness of advanced ICIs, enrolled 82 Italian centers from October 2019 to January 2020. primary endpoint was time-adjusted incidence influenza-like illness (ILI)...
The primary aim of World Journal
Glioblastoma (GBM) is a very poor-prognosis brain tumor. To date, maximal excision followed by radiochemotherapy, in 30 fractions, the standard approach. Limited data are present literature about hypofractionated radiotherapy (hypo-RT) GBM poor prognosis patients. Thus, this retrospective study was conducted to evaluate efficacy and toxicity of hypo-RT with simultaneous integrated boost (SIB) association temozolomide (TMZ) patient setting.Poor-prognosis patients underwent surgery (complete,...
Purpose. For recurrent high-grade gliomas (HGG), no standard therapeutic approach has been reported; thus, surgery, chemotherapy, and re-irradiation (re-RT) may all be proposed. The aim of the study was to evaluate safety efficacy re-RT by radiosurgery or fractionated stereotactic radiotherapy (SRS/FSRT) in association chemotherapy patients with HGG. Material/Methods: All histological diagnosis HGG that suffered disease diagnosed magnetic resonance imaging (MRI), according Response...
The prospective multicentre observational INVIDIa-2 study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving immune checkpoint inhibitors (ICI). In this secondary analysis original trial, we aimed to assess outcomes immunotherapy based on vaccine administration.The enrolled solid tumours ICI at 82 Italian Oncology Units from Oct 1, 2019, Jan 31, 2020. trial's primary endpoint was time-adjusted incidence influenza-like illness (ILI)...